JP2004506604A - Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法 - Google Patents

Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法 Download PDF

Info

Publication number
JP2004506604A
JP2004506604A JP2001569403A JP2001569403A JP2004506604A JP 2004506604 A JP2004506604 A JP 2004506604A JP 2001569403 A JP2001569403 A JP 2001569403A JP 2001569403 A JP2001569403 A JP 2001569403A JP 2004506604 A JP2004506604 A JP 2004506604A
Authority
JP
Japan
Prior art keywords
compound
lpa
edg
alkyl
lpa receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001569403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004506604A5 (https=
Inventor
ミラー　デュアン　ディー．
ティギー　ガボー
ダルトン　ジェームズ　ティー．
サーダー　ビニート　エム．
エルロド　ダン　ビー．
シュー　ヒュインピン
ベイカー　ダニエル　エル．
ワン　ディーン
リリオム　カロリー
フィッシャー　デイビッド　ジェイ．
ヴィラッグ　タマス
ヌッサー　ノラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Oftennessee Research Corp
Original Assignee
University Oftennessee Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Oftennessee Research Corp filed Critical University Oftennessee Research Corp
Publication of JP2004506604A publication Critical patent/JP2004506604A/ja
Publication of JP2004506604A5 publication Critical patent/JP2004506604A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/4028—Esters of poly(thio)phosphonic acids containing no further substituents than -PO3H2 groups in free or esterified form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/17—Esters of thiophosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001569403A 2000-03-17 2001-03-19 Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法 Pending JP2004506604A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19037000P 2000-03-17 2000-03-17
PCT/US2001/008729 WO2001071022A2 (en) 2000-03-17 2001-03-19 Lpa receptor agonists and antagonists and methods of use

Publications (2)

Publication Number Publication Date
JP2004506604A true JP2004506604A (ja) 2004-03-04
JP2004506604A5 JP2004506604A5 (https=) 2008-03-06

Family

ID=22701059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001569403A Pending JP2004506604A (ja) 2000-03-17 2001-03-19 Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法

Country Status (13)

Country Link
US (2) US6875757B2 (https=)
EP (2) EP1263752B1 (https=)
JP (1) JP2004506604A (https=)
KR (1) KR100874392B1 (https=)
AT (1) ATE380187T1 (https=)
AU (1) AU4926301A (https=)
CA (1) CA2402038C (https=)
CY (1) CY1107214T1 (https=)
DE (1) DE60131730T2 (https=)
DK (1) DK1263752T3 (https=)
ES (1) ES2298227T3 (https=)
PT (1) PT1263752E (https=)
WO (1) WO2001071022A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003099765A1 (ja) * 2002-05-28 2005-09-22 小野薬品工業株式会社 β−アラニン誘導体およびその用途
WO2010016590A1 (ja) * 2008-08-07 2010-02-11 国立大学法人 長崎大学 全身性疼痛症候群の治療または予防薬

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use
DK1263752T3 (da) * 2000-03-17 2008-04-14 Univ Tennessee Res Corp LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
EP1361872A4 (en) 2000-10-03 2004-05-19 Univ Virginia NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS
US7064217B2 (en) 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
ES2312588T3 (es) * 2001-07-17 2009-03-01 Ono Pharmaceutical Co., Ltd. Regulacion de la secrecion del jugo pancreatico que comprende un agente de regulacion del receptor del lpa.
WO2003068931A2 (en) * 2002-02-13 2003-08-21 The Scripps Research Institute Purification of the leading front migratory cells
DE10225651A1 (de) * 2002-06-08 2003-12-24 Aventis Pharma Gmbh Verfahren zur Identifizierung von Agonisten oder Antagonisten für den GPR45like/GPR63 Rezeptor
US7300764B2 (en) 2002-06-08 2007-11-27 Sanofi-Aventis Deutschland Gmbh Method for identifying agonists and antagonists of the GPR45-like/GPR63 receptor
EP1550461A1 (en) 2002-06-26 2005-07-06 Ono Pharmaceutical Co., Ltd. Remedy for chronic disease
CA2533587A1 (en) * 2002-07-30 2004-02-05 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
AU2003276221A1 (en) * 2002-11-13 2004-06-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with endothelial differentiation, sphingolipid g-protein-coupled receptor 4 (edg4)
EP1579866A4 (en) * 2002-12-12 2009-07-29 Takeda Pharmaceutical NEW USE OF EDG RECEPTORS
US7524638B1 (en) * 2003-06-27 2009-04-28 Osi Pharmaceuticals, Inc. Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease
WO2005009469A1 (ja) * 2003-07-28 2005-02-03 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
EP2433946B1 (en) * 2003-10-09 2016-04-20 University of Tennessee Research Foundation LPA receptor agonists and antagonists and methods of use
WO2005041899A2 (en) * 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7820703B2 (en) 2004-05-06 2010-10-26 University Of Virginia Patent Foundation Lysophosphatidic acid receptor selective antagonists
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
MX2007001661A (es) * 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
JP2008522977A (ja) * 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
AU2006214314B2 (en) 2005-02-14 2012-02-09 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
US20070078111A1 (en) 2005-07-19 2007-04-05 Gabor Tigyi LPA2 receptor agonist inhibitors of CFTR
KR20080086546A (ko) * 2006-01-27 2008-09-25 유니버시티 오브 버지니아 페이턴트 파운데이션 신경병증성 통증의 치료 방법
AU2007212193A1 (en) * 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
CA2669102A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
AU2007323557A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
CA2669104A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
CA2686735A1 (en) 2007-05-04 2008-11-13 Mdrna, Inc. Amino acid lipids and uses thereof
CN101358609A (zh) * 2007-08-03 2009-02-04 富准精密工业(深圳)有限公司 风扇转子
US9034820B2 (en) 2011-03-14 2015-05-19 Hsinyu Lee Method and composition for modulating erythropoiesis
HK1199259A1 (en) 2011-08-15 2015-06-26 Intermune, Inc. Lysophosphatidic acid receptor antagonists
EP2858635A1 (en) * 2012-06-11 2015-04-15 The Regents of The University of California Inhibitors of hippo-yap signaling pathway
CA2935677C (en) * 2013-12-30 2022-07-26 Rama Krishna Reddy SINGIDI Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5687590A (en) * 1979-12-19 1981-07-16 Yoshitomi Pharmaceut Ind Ltd Diphosphoglycerine derivative
JPS59104310A (ja) * 1982-12-07 1984-06-16 Lion Corp 口腔用組成物
EP0340759A1 (en) * 1988-05-06 1989-11-08 MAGIS FARMACEUTICI S.p.A. Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB861463A (en) 1957-05-03 1961-02-22 Ciba Ltd Process for the manufacture of phosphoric acid esters and piperazine and morpholine derivatives
US3639571A (en) * 1970-01-29 1972-02-01 Samuel Turesky Composition and method for retarding plaque and dental calculus
US4670575A (en) * 1984-06-05 1987-06-02 Kao Corporation Process for purification of phosphoric mono esters
WO1990010014A1 (fr) 1989-02-28 1990-09-07 Teijin Limited Nouveau derive de vitamine b12, sa production et son application
JPH02250892A (ja) 1989-03-24 1990-10-08 Idemitsu Kosan Co Ltd 新規フェロセン誘導体，それを含有する界面活性剤及び有機薄膜の製造方法
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5565439A (en) 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
WO1994023748A1 (en) 1993-04-08 1994-10-27 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5480877A (en) 1993-11-02 1996-01-02 Wisconsin Alumni Research Foundation Use of lysophosphatidic acids to enhance fibronectin binding
GB9618634D0 (en) * 1996-09-06 1996-10-16 Univ Southampton Anti cancer drugs
EP1024812B1 (en) 1997-03-19 2007-01-24 Sky High, LLC Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
CA2301921A1 (en) 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
US5945522A (en) * 1997-12-22 1999-08-31 Genset Prostate cancer gene
AU3191599A (en) * 1998-03-18 1999-10-11 Lxr Biotechnology Inc. Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
DK1263752T3 (da) * 2000-03-17 2008-04-14 Univ Tennessee Res Corp LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5687590A (en) * 1979-12-19 1981-07-16 Yoshitomi Pharmaceut Ind Ltd Diphosphoglycerine derivative
JPS59104310A (ja) * 1982-12-07 1984-06-16 Lion Corp 口腔用組成物
EP0340759A1 (en) * 1988-05-06 1989-11-08 MAGIS FARMACEUTICI S.p.A. Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003099765A1 (ja) * 2002-05-28 2005-09-22 小野薬品工業株式会社 β−アラニン誘導体およびその用途
JP4596314B2 (ja) * 2002-05-28 2010-12-08 小野薬品工業株式会社 β−アラニン誘導体およびその用途
WO2010016590A1 (ja) * 2008-08-07 2010-02-11 国立大学法人 長崎大学 全身性疼痛症候群の治療または予防薬
US8802706B2 (en) 2008-08-07 2014-08-12 Nagasaki University Method for treating fibromyalgia
JP5692746B2 (ja) * 2008-08-07 2015-04-01 国立大学法人 長崎大学 全身性疼痛症候群の治療または予防薬
US9265751B2 (en) 2008-08-07 2016-02-23 Nagasaki University Methods for treating chronic pain

Also Published As

Publication number Publication date
DK1263752T3 (da) 2008-04-14
ATE380187T1 (de) 2007-12-15
AU4926301A (en) 2001-10-03
EP1263752A4 (en) 2003-07-30
CA2402038C (en) 2011-03-15
PT1263752E (pt) 2008-03-18
EP1263752B1 (en) 2007-12-05
US6875757B2 (en) 2005-04-05
DE60131730T2 (de) 2008-11-20
EP1918287A2 (en) 2008-05-07
US20030027800A1 (en) 2003-02-06
KR100874392B1 (ko) 2008-12-17
WO2001071022A2 (en) 2001-09-27
CA2402038A1 (en) 2001-09-27
DE60131730D1 (de) 2008-01-17
EP1918287A3 (en) 2008-08-20
KR20020082890A (ko) 2002-10-31
ES2298227T3 (es) 2008-05-16
CY1107214T1 (el) 2012-11-21
EP1263752A2 (en) 2002-12-11
US20050261252A1 (en) 2005-11-24
WO2001071022A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
JP2004506604A (ja) Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法
US7217704B2 (en) LPA receptor agonists and antagonists and methods of use
JP2005508319A (ja) Ｌｐａ受容体アゴニストおよびアンタゴニストならびにこれらの使用法
AU2002336595A1 (en) LPA receptor agonists and antagonists and methods of use
AU2001249263B2 (en) LPA receptor agonists and antagonists and methods of use
CA2821433C (en) Lpa receptor agonists and antagonists and methods of use
AU2001249263A1 (en) LPA receptor agonists and antagonists and methods of use
AU2007202615A1 (en) LPA receptor agonists and antagonists and methods of use
Sardar Design and synthesis of phospholipid growth factor receptor inhibitors
US20080071116A1 (en) Modulators of Lysophosphatidic Acid (Lpa) Signaling and the Use Thereof
Durgam Design, synthesis and evaluation of novel ligands for lysophosphatidic acid receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080115

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110808